High expression of nucleobindin 2 mRNA: An independent prognostic factor for overall survival of patients with prostate cancer

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2025-2028

  Zhang, Hongtuan ^a   Qi, Can ^a   Wang, Andi ^a   Li, Liang ^a   Xu, Yong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

NUCB2; overall survival; prognostic factor; prostate cancer

Indexed keywords

MEMBRANE PROTEIN; MESSENGER RNA; NUCLEOBINDIN 2; UNCLASSIFIED DRUG;

ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PROGNOSIS; CANCER STAGING; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION;

CALCIUM-BINDING PROTEINS; DNA-BINDING PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NERVE TISSUE PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84886233382     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1268-z     Document Type: Article

References (17)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA Cancer J Clin. 2011;61:212-36.
3. Zhang H, Qi C, Li L, Luo F, Xu Y. Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res. 2013;32:56.
4. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer. 2000;88(12 Suppl):3009-14.
5. Miura K, Titani K, Kurosawa Y, Kanai Y. Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure. Biochem Biophys Res Commun. 1992;187(1):375-80.
6. Barnikol-Watanabe S, Gross NA, Götz H, Henkel T, Karabinos A, Kratzin H, et al. Human protein NEFA, a novel DNA binding/EF-hand/leucine zipper protein. Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Biol Chem Hoppe Seyler. 1994;375(8):497-512.
7. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709-12.
8. Taniguchi N, Taniura H, Niinobe M, Takayama C, Tominaga-Yoshino K, Ogura A, et al. The postmitotic growth suppressor necdin interacts with a calcium-binding protein (NEFA) in neuronal cytoplasm. J Biol Chem. 2000;275(41):31674-81.
9. Islam A, Adamik B, Hawari FI, Ma G, Rouhani FN, Zhang J, et al. Extracellular TNFR1 release requires the calcium-dependent formation of a nucleobindin 2-ARTS-1 complex. J Biol Chem. 2006;281(10):6860-73.
10. García-Galiano D, Navarro VM, Gaytan F, Tena-Sempere M. Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. J Mol Endocrinol. 2010;45(5):281-90.
11. Suzuki S, Takagi K, Miki Y, Onodera Y, Akahira J, Ebata A, et al. Nucleobindin 2 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 2012;103(1):136-43.
12. Zhang H, Ma H, Xu Y, Li L. Association of SMAD7 rs12953717 polymorphism with cancer: a meta-analysis. PLoS ONE. 2013;8:e58170.
13. Zhang H, Ma H, Li L, Zhang Z, Xu Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis. PLoS One. 2013;8:e69366.
14. Zhang H, Li L, Xu Y. CYP1B1 polymorphisms and susceptibility to prostate cancer: a meta-analysis. PLoS One. 2013;8:e68634.
15. Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, et al. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J Exp Clin Cancer Res. 2012;31:32.
16. Filella X, Foj L, Milà M, Augé JM, Molina R, Jiménez W. PCA3 in the detection and management of early prostate cancer. Tumor Biol. 2013;34(3):1337-47.
17. Delgado PO, Alves BC, Gehrke Fde S, Kuniyoshi RK, Wroclavski ML, Del Giglio A, et al. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumor Biol. 2013;34(2):983-6.